دورية أكاديمية
Disulfide-masked iron prochelators: Effects on cell death, proliferation, and hemoglobin production.
| العنوان: | Disulfide-masked iron prochelators: Effects on cell death, proliferation, and hemoglobin production. |
|---|---|
| المؤلفون: | Akam EA; Department of Chemistry and Biochemistry, The University of Arizona, United States., Utterback RD; Department of Chemistry and Biochemistry, The University of Arizona, United States., Marcero JR; Department of Microbiology and Department of Biochemistry and Molecular Biology, University of Georgia, United States., Dailey HA; Department of Microbiology and Department of Biochemistry and Molecular Biology, University of Georgia, United States., Tomat E; Department of Chemistry and Biochemistry, The University of Arizona, United States. Electronic address: tomat@email.arizona.edu. |
| المصدر: | Journal of inorganic biochemistry [J Inorg Biochem] 2018 Mar; Vol. 180, pp. 186-193. Date of Electronic Publication: 2018 Jan 04. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 7905788 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3344 (Electronic) Linking ISSN: 01620134 NLM ISO Abbreviation: J Inorg Biochem Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, Elsevier. |
| مواضيع طبية MeSH: | Cell Death/*drug effects , Cell Proliferation/*drug effects , Disulfides/*chemistry , Hemoglobins/*biosynthesis , Hydrazones/*chemistry , Hydrazones/*pharmacology , Iron Chelating Agents/*chemistry , Iron Chelating Agents/*pharmacology, Animals ; Cell Line, Tumor ; G1 Phase/drug effects ; Humans ; Mice ; S Phase/drug effects ; Thiosemicarbazones/chemistry |
| مستخلص: | The iron metabolism of malignant cells, which is altered to ensure higher acquisition and utilization, motivates the investigation of iron chelation strategies in cancer treatment. In a prochelation approach aimed at increasing intracellular specificity, disulfide reduction/activation switches are incorporated on iron-binding scaffolds resulting in intracellularly activated scavengers. Herein, this strategy is applied to several tridentate donor sets including thiosemicarbazones, aroylhydrazones and semicarbazones. The novel prochelator systems are antiproliferative in breast adenocarcinoma cell lines (MCF-7 and metastatic MDA-MB-231) and do not result in the intracellular generation of oxidative stress. Consistent with iron deprivation, the tested prochelators lead to cell-cycle arrest at the G (Copyright © 2017 Elsevier Inc. All rights reserved.) |
| References: | J Biol Chem. 2010 Aug 27;285(35):26753-26759. (PMID: 20522548) J Lab Clin Med. 1988 Oct;112(4):433-6. (PMID: 2459279) PLoS One. 2015 Oct 13;10(10):e0139929. (PMID: 26460540) J Inorg Biochem. 2008 Dec;102(12):2130-5. (PMID: 18835041) J Inorg Biochem. 2010 Nov;104(11):1224-8. (PMID: 20719391) Biomarkers. 2012 Dec;17(8):671-91. (PMID: 22900535) J Biol Chem. 2015 Apr 10;290(15):9588-603. (PMID: 25720491) Free Radic Biol Med. 2001 Jun 1;30(11):1191-212. (PMID: 11368918) J Biol Chem. 2012 Oct 12;287(42):35768-35778. (PMID: 22915594) Chem Biol Interact. 2012 May 30;197(2-3):69-79. (PMID: 22521999) Blood. 2009 Oct 1;114(14):3064-73. (PMID: 19589922) Biotechniques. 2016 Aug 01;61(2):83-91. (PMID: 27528073) Blood. 1997 Jan 1;89(1):1-25. (PMID: 8978272) Dalton Trans. 2013 Mar 7;42(9):3220-9. (PMID: 23232973) Nat Med. 1996 Jan;2(1):72-9. (PMID: 8564846) Acta Haematol. 1993;89(2):57-60. (PMID: 8503244) Acc Chem Res. 2016 Nov 15;49(11):2468-2477. (PMID: 27749047) Proteomics. 2006 Mar;6(6):1963-75. (PMID: 16470659) Mol Pharmacol. 2011 Oct;80(4):598-609. (PMID: 21719465) Breast Cancer Res Treat. 2010 Jan;119(2):283-93. (PMID: 19238537) Antioxid Redox Signal. 2013 Mar 10;18(8):888-98. (PMID: 22909065) Cell. 2017 Jan 26;168(3):344-361. (PMID: 28129536) Biochim Biophys Acta. 2009 Jul;1790(7):702-17. (PMID: 18485918) Biochim Biophys Acta. 2002 Oct 2;1603(1):31-46. (PMID: 12242109) Pharmacol Rev. 2005 Dec;57(4):547-83. (PMID: 16382108) Dalton Trans. 2007 Nov 21;(43):5031-42. (PMID: 17992288) Cancer Res. 1956 Feb;16(2):167-70. (PMID: 13293659) Nat Rev Cancer. 2013 May;13(5):342-55. (PMID: 23594855) J Inorg Biochem. 2016 Sep;162:31-43. (PMID: 27297691) ACS Chem Biol. 2010 Jun 18;5(6):603-10. (PMID: 20455574) Exp Parasitol. 2011 Dec;129(4):381-7. (PMID: 21939658) Biochim Biophys Acta. 1982 Feb 10;720(1):96-105. (PMID: 7059619) J Biol Chem. 1996 Aug 23;271(34):20291-9. (PMID: 8702762) Chem Rev. 2013 Jul 10;113(7):5071-109. (PMID: 23577659) Biol Chem. 2009 Mar;390(3):191-214. (PMID: 19166318) Am J Hematol. 2009 Mar;84(3):170-6. (PMID: 19140186) Angew Chem Int Ed Engl. 2007;46(10):1716-8. (PMID: 17397084) Eur J Biochem. 1994 Mar 15;220(3):683-92. (PMID: 8143723) Proc Natl Acad Sci U S A. 1971 Feb;68(2):378-82. (PMID: 5277089) Blood. 2006 May 15;107(10):4159-67. (PMID: 16424395) Metallomics. 2014 Oct;6(10):1905-12. (PMID: 25100578) Biochim Biophys Acta. 2004 Apr 1;1691(1):41-50. (PMID: 15053923) Proc Natl Acad Sci U S A. 1976 Apr;73(4):1232-6. (PMID: 177980) J Inorg Biochem. 2011 Nov;105(11):1422-31. (PMID: 21955844) Biochim Biophys Acta. 2016 Dec;1863(12):2859-2867. (PMID: 27627839) Cancer Lett. 2014 May 28;347(1):1-14. (PMID: 24486738) J Photochem Photobiol B. 2006 Feb 1;82(2):127-31. (PMID: 16307890) J Med Chem. 2009 Sep 10;52(17):5271-94. (PMID: 19601577) Biochim Biophys Acta. 1989 Aug 15;1012(3):243-53. (PMID: 2758037) Antioxid Redox Signal. 2013 Mar 10;18(8):973-1006. (PMID: 22424293) Mol Pharmacol. 2012 Jul;82(1):105-14. (PMID: 22508546) Acc Chem Res. 2015 Nov 17;48(11):2935-46. (PMID: 26513450) Cancer Res. 2011 Sep 1;71(17):5871-80. (PMID: 21750178) Cancer Res. 1958 Dec;18(11):1290-300. (PMID: 13608436) J Am Chem Soc. 2016 Nov 2;138(43):14338-14346. (PMID: 27768321) Biochem J. 2010 May 13;428(2):183-90. (PMID: 20331437) J Vis Exp. 2010 Nov 26;(45):. (PMID: 22158024) PLoS One. 2014 Nov 13;9(11):e112059. (PMID: 25393531) J Biol Chem. 1984 Oct 10;259(19):11695-700. (PMID: 6090444) J Am Chem Soc. 2006 Sep 27;128(38):12424-5. (PMID: 16984186) Blood. 2007 Aug 15;110(4):1353-8. (PMID: 17485548) J Med Chem. 2012 Aug 23;55(16):7230-44. (PMID: 22861499) PLoS One. 2016 Nov 2;11(11):e0166164. (PMID: 27806101) Pharmacol Res. 2015 Oct;100:255-60. (PMID: 26318762) Nat Chem Biol. 2016 Sep;12(9):680-5. (PMID: 27376690) Biochem Biophys Res Commun. 1979 Jun 27;88(4):1382-90. (PMID: 289386) Sci Transl Med. 2010 Aug 4;2(43):43ra56. (PMID: 20686179) Blood. 2007 Jul 1;110(1):125-32. (PMID: 17376890) Adv Drug Deliv Rev. 2003 Feb 10;55(2):199-215. (PMID: 12564977) Bioconjug Chem. 2016 Aug 17;27(8):1807-12. (PMID: 27471913) Angew Chem Int Ed Engl. 2012 Jul 23;51(30):7445-8. (PMID: 22730309) Dalton Trans. 2013 Jun 14;42(22):7846-9. (PMID: 23591852) Cell Biochem Funct. 2006 Nov-Dec;24(6):555-9. (PMID: 16142688) Free Radic Biol Med. 2012 Jan 1;52(1):1-6. (PMID: 22027063) |
| معلومات مُعتمدة: | P30 CA023074 United States CA NCI NIH HHS; P30 ES006694 United States ES NIEHS NIH HHS; L30 DK096501 United States DK NIDDK NIH HHS; U54 DK110858 United States DK NIDDK NIH HHS; R01 DK096051 United States DK NIDDK NIH HHS |
| فهرسة مساهمة: | Keywords: Anticancer; Cell-cycle arrest; Hemoglobin production; Iron; Prochelator |
| المشرفين على المادة: | 0 (Disulfides) 0 (Hemoglobins) 0 (Hydrazones) 0 (Iron Chelating Agents) 0 (Thiosemicarbazones) |
| تواريخ الأحداث: | Date Created: 20180112 Date Completed: 20181011 Latest Revision: 20231112 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC5956897 |
| DOI: | 10.1016/j.jinorgbio.2017.12.016 |
| PMID: | 29324291 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1873-3344 |
|---|---|
| DOI: | 10.1016/j.jinorgbio.2017.12.016 |